AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8345495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg) after 12 hours of abstention
Number of subjects: 0
Study 8345495 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 12 hours of abstention
Number of subjects: 0
Study 8345495 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine and placebo phases
Number of subjects: 0
Study 2822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent immunoglobulins or CMV-hyperimmunoglobulin
Number of subjects: 0
Study 2822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulins
Number of subjects: 0
Study 2822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulin against varicella zoster
Number of subjects: 0
Study 2822997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperimmunoglobulins against pseudomonas aeruginosa
Number of subjects: 0
Study 11557910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 20
Study 11557910 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg)
Number of subjects: 20
Study 30478716 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdose LSD (5, 10, and 20 μg)
Number of subjects: 0
Study 30478716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30203028 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 0
Study 30203028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27814867 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology tape applied to quadriceps muscle
Number of subjects: 30
Study 27814867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no kinesiology tape)
Number of subjects: 30
Study 24938502 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine transdermal patch + physical exercises
Number of subjects: 40
Study 24938502 — intervention group
Group type: COMPARATOR
Intervention: Rivastigmine transdermal patch alone
Number of subjects: 40
Study 22800889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 50 µg×kg(‐1)×min(‐1) (low-dose group)
Number of subjects: 90
Study 22800889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine 70 µg×kg(‐1)×min(‐1) (high-dose group)
Number of subjects: 90
Study 22800889 — intervention group
Group type: COMPARATOR
Intervention: Saline 1 ml/min (control group)
Number of subjects: 90
Study 20625015 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 217
Study 20625015 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 217
Study 17698695 — intervention group
Group type: EXPERIMENTAL
Intervention: BHT‐3009 (0.5 mg, 1.5 mg, and 3 mg) administered as intramuscular injections at weeks 1, 3, 5, and 9
Number of subjects: 30
Study 17698695 — intervention group
Group type: EXPERIMENTAL
Intervention: BHT‐3009 with 80 mg of daily oral atorvastatin calcium
Number of subjects: 30
Study 17698695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15647704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 15647704 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 0
Study 15647704 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral therapy
Number of subjects: 0
Study 12401614 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1% (2 mL)
Number of subjects: 159
Study 12401614 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (10 mg, 2 mL)
Number of subjects: 159
Study 12401614 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL)
Number of subjects: 159
Study 10363691 — intervention group
Group type: EXPERIMENTAL
Intervention: N/R‐ATS (rabbit polyclonal antithymocyte serum)
Number of subjects: 465
Study 10363691 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 465
Study 10363691 — intervention group
Group type: COMPARATOR
Intervention: No induction (no antithymocyte antibodies)
Number of subjects: 465
Study 10363691 — intervention group
Group type: EXPERIMENTAL
Intervention: N/R‐ATS centers
Number of subjects: 465
Study 10363691 — intervention group
Group type: EXPERIMENTAL
Intervention: OKT3 centers
Number of subjects: 465
Study 10363691 — intervention group
Group type: COMPARATOR
Intervention: No IND centers
Number of subjects: 465
Study 7480517 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 cigarettes smoked prior
Number of subjects: 10
Study 7480517 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cigarettes smoked prior
Number of subjects: 10
Study 7480517 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cigarettes smoked prior
Number of subjects: 10
Study 7480517 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 cigarettes smoked prior
Number of subjects: 10
Study 7480517 — intervention group
Group type: COMPARATOR
Intervention: 6 hours of no smoking prior
Number of subjects: 10
Study 2268438 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative autologous blood transfusion (AT)
Number of subjects: 20
Study 2268438 — intervention group
Group type: COMPARATOR
Intervention: Control group (no autologous transfusion)
Number of subjects: 20
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 55
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide combined with amiloride (AHCT)
Number of subjects: 55
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of timolol and AHCT
Number of subjects: 55
Study 7002427 — intervention group
Group type: COMPARATOR
Intervention: AHCT
Number of subjects: 55
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Timolol + AHCT)
Number of subjects: 55
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol and AHCT
Number of subjects: 55
Study 7002427 — intervention group
Group type: EXPERIMENTAL
Intervention: PRA determination
Number of subjects: 55
Study 30410041 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD EOW
Number of subjects: 348
Study 30410041 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD Weekly
Number of subjects: 348
Study 30410041 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 348
Study 28992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan 100 mg (increased to 200 mg at week 4, and 400 mg at week 10 if BP >140/90 mm Hg)
Number of subjects: 588
Study 28992296 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (various doses as above)
Number of subjects: 588
Study 28992296 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan 10 mg (increased to 20 mg at week 4, and 40 mg at week 10 if BP >140/90 mm Hg)
Number of subjects: 588
Study 25773405 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive management initiated within 1 week of diagnosis of type 1 diabetes
Number of subjects: 67
Study 25773405 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 67
Study 25773405 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 67
Study 25773405 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide
Number of subjects: 67
Study 23721895 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial spin-labeling (ASL)
Number of subjects: 49
Study 23721895 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched cohort of 36 patients with no cerebrovascular events)
Number of subjects: 49
Study 21545996 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard anterior colporrhaphy
Number of subjects: 114
Study 21545996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralateral colporrhaphy
Number of subjects: 114
Study 21545996 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy plus polyglactin 910 mesh
Number of subjects: 114
Study 21545996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 114
Study 19426116 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 0
Study 19426116 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies targeting different pathways of T-cell activation
Number of subjects: 0
Study 17539025 — intervention group
Group type: EXPERIMENTAL
Intervention: High HBV DNA levels prior to chemotherapy
Number of subjects: 188
Study 17539025 — intervention group
Group type: EXPERIMENTAL
Intervention: High total bilirubin
Number of subjects: 188
Study 17539025 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV infection
Number of subjects: 188
Study 15171772 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency treatment on the left side of the face
Number of subjects: 10
Study 15171772 — intervention group
Group type: COMPARATOR
Intervention: Nontreated side (control)
Number of subjects: 10
Study 11356768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with water placebo (WP)
Number of subjects: 17
Study 11356768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with 6% CHO beverage
Number of subjects: 17
Study 11356768 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (1,300 mg) with 6% CHO+G beverage
Number of subjects: 17
Study 11356768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) with water placebo (WP)
Number of subjects: 17
Study 11356768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) with 6% CHO beverage
Number of subjects: 17
Study 11356768 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) with 6% CHO+G beverage
Number of subjects: 17
Study 10806751 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a 150 micrograms/day subcutaneously for three months
Number of subjects: 75
Study 10806751 — intervention group
Group type: COMPARATOR
Intervention: mifepristone 12.5 mg/day po for three months
Number of subjects: 75
Study 8283898 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuit (Duraflo II)
Number of subjects: 30
Study 8283898 — intervention group
Group type: COMPARATOR
Intervention: Uncoated extracorporeal circuit
Number of subjects: 30
Study 2743060 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental attention-training programme
Number of subjects: 20
Study 2743060 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo
Number of subjects: 20
Study 2743060 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 20
Study 29582411 — intervention group
Group type: EXPERIMENTAL
Intervention: modified natural cycle frozen-thawed embryo transfer (mNC-FET)
Number of subjects: 463
Study 28821525 — intervention group
Group type: EXPERIMENTAL
Intervention: Washed allogeneic RBC transfusion
Number of subjects: 170
Study 28821525 — intervention group
Group type: COMPARATOR
Intervention: Standard allogeneic RBC transfusion
Number of subjects: 170
Study 26365268 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy enhancing interventions (structured discussion, testimonial video, reminder)
Number of subjects: 86
Study 26365268 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy and home-based pelvic floor muscle exercises
Number of subjects: 86
Study 26365268 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 86
Study 24265734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active office (n = 19)
Number of subjects: 62
Study 24265734 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Workstation and promotion of incidental office activity
Number of subjects: 62
Study 24265734 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physical activity (n = 14)
Number of subjects: 62
Study 24265734 — intervention group
Group type: EXPERIMENTAL
Intervention: Office ergonomics (n = 29)
Number of subjects: 62
Study 21517170 — intervention group
Group type: EXPERIMENTAL
Intervention: Telic state (n = 22)
Number of subjects: 55
Study 21517170 — intervention group
Group type: COMPARATOR
Intervention: Paratelic state (n = 33)
Number of subjects: 55
Study 18512710 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg on days 1 and 15)
Number of subjects: 0
Study 18512710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17023704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g) plus alpha-tocopherol (800 IU)
Number of subjects: 30
Study 17023704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 14622640 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention clinic attendance
Number of subjects: 179
Study 14622640 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported data from interviews
Number of subjects: 179
Study 11271082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-time curve (P-T) with minimum flow delay
Number of subjects: 11
Study 11271082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-time curve (P-T) with maximum flow delay
Number of subjects: 11
Study 11271082 — intervention group
Group type: COMPARATOR
Intervention: Pressure-volume curve (P-V)
Number of subjects: 11
Study 9074381 — intervention group
Group type: EXPERIMENTAL
Intervention: Competency-based trauma teaching program
Number of subjects: 67
Study 9074381 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 127) taught by discipline-based lectures
Number of subjects: 67
Study 8400756 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 4 micrograms/kg
Number of subjects: 77
Study 8400756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 3518646 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hypothermia with cold potassium cardioplegia (group 1)
Number of subjects: 100
Study 3518646 — intervention group
Group type: COMPARATOR
Intervention: Topical hypothermia with local interruption of the coronary circulation (group 2)
Number of subjects: 100
Study 31078666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 µg twice-daily
Number of subjects: 54
Study 31078666 — intervention group
Group type: COMPARATOR
Intervention: Titrated insulin glargine (iGlar)
Number of subjects: 54
Study 31078666 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 54
Study 28523391 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus low-level diode laser (630-670 nm, 1.875 J/cm2) for five consecutive days
Number of subjects: 60
Study 28523391 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus low-level diode laser (630-670 nm, 1.875 J/cm2) for ten consecutive days
Number of subjects: 60
Study 28523391 — intervention group
Group type: COMPARATOR
Intervention: SRP (scaling and root planing)
Number of subjects: 60
Study 26219568 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 316
Study 26219568 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 316
Study 23689954 — intervention group
Group type: EXPERIMENTAL
Intervention: Exchange Reamed Nailing (ERN)
Number of subjects: 48
Study 23689954 — intervention group
Group type: COMPARATOR
Intervention: Augmentation Compression Plating (ACP)
Number of subjects: 48
Study 21244590 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy treatment (specific dosage and duration not mentioned)
Number of subjects: 20
Study 21244590 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with parents about trial design
Number of subjects: 20
Study 19631303 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg GLP-2
Number of subjects: 100
Study 19631303 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 mg GLP-2
Number of subjects: 100
Study 19631303 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.2 mg GLP-2
Number of subjects: 100
Study 19631303 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 100
Study 17589373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 157
Study 17589373 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 157
Study 17589373 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nelfinavir and efavirenz
Number of subjects: 157
Study 17589373 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine-lamivudine
Number of subjects: 157
Study 17589373 — intervention group
Group type: COMPARATOR
Intervention: Didanosine-stavudine
Number of subjects: 157
Study 14634379 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin daily
Number of subjects: 60
Study 14634379 — intervention group
Group type: COMPARATOR
Intervention: Oral floroglucine‐trimetossibenzene 3 times daily
Number of subjects: 60
Study 10735806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg urapidil
Number of subjects: 120
Study 10735806 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg/kg clonidine
Number of subjects: 120
Study 10735806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg meperidine
Number of subjects: 120
Study 10735806 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (placebo)
Number of subjects: 120
Study 8872649 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO‐E (5.5% CHO‐electrolyte solution)
Number of subjects: 8
Study 8872649 — intervention group
Group type: COMPARATOR
Intervention: Pl (placebo)
Number of subjects: 8
Study 1891212 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with postoperative 5-fluorouracil (5-FU)
Number of subjects: 17
Study 1891212 — intervention group
Group type: COMPARATOR
Intervention: Full-thickness filtering procedure with modified shell tamponade technique
Number of subjects: 17
Study 6134039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (twice-daily as single-drug therapy)
Number of subjects: 78
Study 6134039 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol (given every 6 hours)
Number of subjects: 78
Study 6134039 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78
Study 6134039 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin and chloramphenicol
Number of subjects: 78
Study 3932361 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent Pseudomonas vaccine (three or four dose schedule)
Number of subjects: 0
Study 3932361 — intervention group
Group type: COMPARATOR
Intervention: Control group (two dose schedule)
Number of subjects: 0
Study 29763504 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype optoelectronic CA-navigation device
Number of subjects: 20
Study 29763504 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach
Number of subjects: 20
Study 27614458 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentin-1
Number of subjects: 637
Study 27614458 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin
Number of subjects: 637
Study 27614458 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoprotegerin (OPG)
Number of subjects: 637
Study 27614458 — intervention group
Group type: COMPARATOR
Intervention: BUA levels in peri-/premenopausal women
Number of subjects: 637
Study 24434794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil (n = 63)
Number of subjects: 128
Study 24434794 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 65)
Number of subjects: 128
Study 22626888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 60
Study 22626888 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 60
Study 20413518 — intervention group
Group type: EXPERIMENTAL
Intervention: Macroalbuminuria (AER >300 mg/24 h)
Number of subjects: 1439
Study 20413518 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuria (AER 30-300 mg/24 h)
Number of subjects: 1439
Study 20413518 — intervention group
Group type: EXPERIMENTAL
Intervention: AER <30 mg/24 h
Number of subjects: 1439
Study 20413518 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population with sustained eGFR <60 ml/min/1.73 m(2)
Number of subjects: 1439
Study 18214668 — intervention group
Group type: EXPERIMENTAL
Intervention: Triarchic body‐pathway relaxation technique (TBRT)
Number of subjects: 19
Study 18214668 — intervention group
Group type: COMPARATOR
Intervention: Music listening
Number of subjects: 19
Study 15671968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Rhino nasal tampon
Number of subjects: 40
Study 15671968 — intervention group
Group type: COMPARATOR
Intervention: Rhino Rocket nasal tampon
Number of subjects: 40
Study 12882849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed diabetes care in clinic A
Number of subjects: 504
Study 12882849 — intervention group
Group type: COMPARATOR
Intervention: Usual (physician-directed) care in clinic B
Number of subjects: 504
Study 12882849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-directed care in clinic B (after 1 year)
Number of subjects: 504
Study 11003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa2a plus amantadine (100 mg twice a day for 48 weeks)
Number of subjects: 119
Study 11003631 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa2a alone (placebo)
Number of subjects: 119
Study 11003631 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa2a plus amantadine
Number of subjects: 119
Study 8625679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Appliance (OA)
Number of subjects: 25
Study 8625679 — intervention group
Group type: COMPARATOR
Intervention: Nasal-Continuous Positive Airway Pressure (N-CPAP)
Number of subjects: 25
Study 1298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum fructosamine in diabetic patients at the beginning of the study
Number of subjects: 300
Study 1298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum fructosamine in diabetic patients at the 12th week visit
Number of subjects: 300
Study 1298563 — intervention group
Group type: COMPARATOR
Intervention: Serum fructosamine in non-diabetic population
Number of subjects: 300
Study 1298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of serum fructosamine with glycosylated haemoglobin
Number of subjects: 300
Study 1298563 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma glucose with fructosamine
Number of subjects: 300
Study 6146371 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiolytic medication
Number of subjects: 91
Study 6146371 — intervention group
Group type: COMPARATOR
Intervention: Brief counselling without anxiolytics
Number of subjects: 91